Fridays vs Mochi Health (2026): prices, structure, verdict

On tirzepatide, Mochi Health↗ is cheaper: $278 versus $359 a month all-in — a $81 monthly gap, $972 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Fridays is cheaper: $175 versus $178 a month all-in — a $3 monthly gap, $36 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Fridays: the record, condensed

Fridays’s tirzepatide program bills $359 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $359 is the whole subscription, which makes Fridays unusually easy to compare and unusually easy to leave.

To place the number: #13 of 17 verified programs, with the floor $144/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $90 a month. A year at this figure: $4,308 monthly-billed.

Start with the load-bearing figure: $175 a month, all-in, is what Fridays charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $175 is the whole subscription, which makes Fridays unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #7 of 20 in the verified semaglutide index — $42/month above the floor (Oak Longevity, $133) — and sits $174 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,100.

Operationally at Fridays: shipping included; commitment annual plan for lowest rate; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Fridays page · visit Fridays ↗

Mochi Health: the record, condensed

Start with the load-bearing figure: $278 a month, all-in, is what Mochi Health charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

A required $79/month membership is part of the deal, and part of the figure above: $199 of medication plus $79 of platform equals the $278 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #4 of 17 verified programs, with the floor $63/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $171 a month. A year at this figure: $3,336 monthly-billed.

Mochi Health’s semaglutide program bills $178 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Inside that $178 sits a mandatory $79-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $99, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #8 of 20 in the verified semaglutide index — $45/month above the floor (Oak Longevity, $133) — and sits $171 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,136.

Operationally at Mochi Health: shipping included; commitment membership recurs monthly; cancellation cancel membership any time; recurs until cancelled; pharmacy named (company-owned compounding facility); states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Mochi Health page · visit Mochi Health ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: Mochi Health at $278, Fridays at $359 — a $81 monthly spread that compounds to $972 over a maintenance year and $1,944 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $81 gap is exactly what it appears to be.

Mochi Health’s total includes a mandatory $79/month membership; Fridays has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $175 (Fridays) against $178 (Mochi Health). $3 a month sounds survivable; $36 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $3 gap is exactly what it appears to be.

Mochi Health’s total includes a mandatory $79/month membership; Fridays has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

A way to feel the $81 monthly gap: over a year it funds 3.5 extra months at Mochi Health’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $1,944, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Fridays $359/mo month-to-month against Mochi Health $278/mo month-to-month. The order holds: Mochi Health leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Fridays $1,077 monthly; Mochi Health $834 monthly — best path favors Mochi Health by $243. 6 months: Fridays $2,154 monthly; Mochi Health $1,668 monthly — best path favors Mochi Health by $486. 12 months: Fridays $4,308 monthly; Mochi Health $3,336 monthly — best path favors Mochi Health by $972. 24 months: Fridays $8,616 monthly; Mochi Health $6,672 monthly — best path favors Mochi Health by $1,944.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Fridays $525 vs Mochi Health $534 — $9 to Fridays. 6 mo: Fridays $1,050 vs Mochi Health $1,068 — $18 to Fridays. 12 mo: Fridays $2,100 vs Mochi Health $2,136 — $36 to Fridays. 24 mo: Fridays $4,200 vs Mochi Health $4,272 — $72 to Fridays.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Fridays publishes “not published”; Mochi Health publishes “most states” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: Mochi Health names its network (company-owned compounding facility); Fridays does not, which shifts the burden of verification onto your intake questions.

Exit terms: Fridays — annual plan for lowest rate; not published. Mochi Health — membership recurs monthly; cancel membership any time; recurs until cancelled.

Evidence: Fridays third-party reported (captured 2026-08-05); Mochi Health source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #13 and #4 of 17: between them lie 8 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #7 and #8 of 20: between them lie 0 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Fridays and Mochi Health

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Fridays: not published; Mochi Health: cancel membership any time; recurs until cancelled) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings